Skip to main content

Table 2 Univariate analysis of prognostic factors for overall survival and progression-free survival

From: Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study

Factor

OS

 

PFS

HR

P Value

 

HR

P Value

Sex (female vs. male)

1.091

0.576

 

1.051

0.78

Age

1.008

0.162

 

1.004

0.489

Mean tumor diameter (cm)

1.102

< 0.001

 

1.119

< 0.001

Albumin g/dL

0.987

0.265

 

0.995

0.667

Total bilirubin u mol/L

1.004

0.002

 

1.002

0.139

AFP > 400 ng/mL

1.868

< 0.001

 

1.941

< 0.001

Child-Pugh B

0.847

0.445

 

0.833

0.437

BCLC B

2.072

< 0.001

 

2.631

< 0.001

Hepatitis B

1.589

0.118

 

1.203

0.534

TACE-RFA

0.205

0

 

0.147

0

Number of tumors

1.089

0.446

 

1.089

0.488

  1. OS overall survival, PFS progression-free survival, HR hazard ratio, AFP alpha-fetoprotein, BCLC Barcelona Clinic Liver Cancer, RFA radiofrequency ablation, TACE transarterial chemoembolization
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us